Who Should Avoid GLP-1 Agonist Weight Loss Medications?
You may have read that weight loss medications can occasionally have serious side effects. Thankfully, most are safe for many people, but certain groups should avoid GLP-1 agonists due to higher risks. In Australia, these drugs are popular for managing obesity and diabetes, but knowing the contraindications helps ensure they're used appropriately. This overview covers the main reasons to avoid them, drawing from Australian guidelines and studies, plus what to do if you're unsure.
Main Contraindications for GLP-1 Agonists
GLP-1 agonists are generally well-tolerated, but they're not suitable for everyone. Key contraindications include:
-
Personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2): Animal studies show a link to thyroid tumors, so these drugs are avoided to prevent potential risks.
-
Pregnancy or breastfeeding: They may harm the fetus or pass into breast milk; use effective contraception if of childbearing age.
-
Known hypersensitivity: If you've had allergic reactions to the drug or its ingredients, it's not safe.
-
Severe gastrointestinal disease: Conditions like gastroparesis (slow stomach emptying) can worsen with these meds.
These are absolute “no-go” situations—your doctor will screen for them before prescribing.


Relative Cautions and Risks
Some situations aren't full contraindications but call for extra caution or monitoring:
-
History of pancreatitis: There's a rare link (about 0.3% risk), so if you've had it before, alternatives might be better.
-
Kidney or liver issues: Dose adjustments or avoidance if severe, as the drugs are processed through these organs.
-
Heart conditions: Generally safe, but discuss if you have a history of heart failure.
-
Young women planning pregnancy: Stop at least 2 months before trying to conceive due to potential risks.
Studies show overall risks are low, but monitoring helps catch issues early.
What to Do If You're Concerned
If any contraindications apply to you, tell your doctor right away—they can suggest other options like lifestyle changes or different meds. Get a full health check before starting, including blood tests and family history review. If symptoms like severe abdominal pain (a pancreatitis sign) appear while on the drug, seek urgent care. In Australia, report concerns to the TGA for safety tracking.
Tips for Safe Use
-
Share your full medical history with your GP.
-
Start at a low dose to watch for reactions.
-
Combine with diet and exercise for best results.
-
Regular follow-ups catch any issues early.
These meds help many, but safety comes first—your doctor can guide you.
Frequently Asked Questions
Who should not take GLP-1 agonists for weight loss?
Those with MTC/MEN2 history, pregnancy, hypersensitivity, or severe GI disease.
Is pancreatitis a contraindication for GLP-1 medications?
A history of it is a caution; discuss risks with your doctor.
Can pregnant women use GLP-1 weight loss drugs?
No—avoid during pregnancy or breastfeeding due to potential harm.
What if I have kidney problems and GLP-1 agonists?
Severe cases may require avoidance or adjustments; consult your GP.
Are GLP-1 agonists safe for everyone in Australia?
No, but they're suitable for most without contraindications—get screened first.
References
-
Forner P, Hocking S. Pharmacotherapy for the management of overweight and obesity. Australian Journal of General Practice Vol. 54, No. 4, April 2025. Read more https://www1.racgp.org.au/getattachment/c09e5a10-b5a6-4911-bbe0-1efdfd298339/Pharmacotherapy-for-the-management-of-overweight-a.aspx
-
Li Y(R), Wu B, Nik C, Wu L, Tse T. Glucagon-like peptide-1 receptor agonists for weight loss: Consider the case for selective pharmacotherapy. Australian Journal of General Practice Vol. 54, No. 4, April 2025. Read more https://www1.racgp.org.au/getattachment/ea60961e-6679-4a96-b340-290571971200/Glucagon-like-peptide-1-receptor-agonists-for-weig.aspx
-
Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists. TGA.gov.au. Published Jun 3, 2025. Read more https://www.tga.gov.au/news/safety-updates/medicines-containing-glp-1-and-dual-gipglp-1-receptor-agonists
-
Glucagon-like peptide-1 receptor agonists for weight loss. RACGP.org.au. Read more https://www1.racgp.org.au/ajgp/2025/april/glucagon-like-peptide-1-receptor-agonists-for-weig
-
The role of GLP‐1 receptor agonists in the management of obesity. MJA.com.au. Published Feb 17, 2025. Read more https://www.mja.com.au/journal/2025/222/3/role-glp-1-receptor-agonists-management-obesity-risks-and-opportunities
-
New safety warning for GLP-1 and dual GIP/GLP-1 receptor agonists. AustralianPrescriber.tg.org.au. Published Aug 12, 2025. Read more https://australianprescriber.tg.org.au/articles/new-safety-warning-for-GLP-1-and-dual-GIP-GLP-1-receptor-agonists.html
-
Clinical Practice Recommendations regarding patients taking GLP-1. ANZCA.edu.au. Published Apr 2, 2025. Read more https://www.anzca.edu.au/getContentAsset/0f35028e-e371-4220-a49a-ddee877051c8/80feb437-d24d-46b8-a858-4a2a28b9b970/Clinical-Practice-Recommendations-Periprocedural-GLP-1RA-use-Apr-2025.pdf
-
2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations. PMC.ncbi.nlm.nih.gov. Read more https://pmc.ncbi.nlm.nih.gov/articles/PMC12420935/
-
Unregulated GLP-1 access under the spotlight. RACGP.org.au. Published Oct 1, 2025. Read more https://www1.racgp.org.au/newsgp/clinical/unregulated-glp-1-access-under-the-spotlight
-
Gastrointestinal adverse events associated with GLP-1 RA in non-obese populations. Nature.com. Published Aug 13, 2025. Read more https://www.nature.com/articles/s41366-025-01859-6
-
GLP-1 weight-loss drugs pose hidden risks for young women. News.flinders.edu.au. Published Sep 9, 2025. Read more https://news.flinders.edu.au/blog/2025/09/09/glp-1-weight-loss-drugs-pose-hidden-risks-for-young-women/